Homology modeling in drug discovery: current trends and applications.

As structural genomics (SG) projects continue to deposit representative 3D structures of proteins, homology modeling methods will play an increasing role in structure-based drug discovery. Although computational structure prediction methods provide a cost-effective alternative in the absence of experimental structures, developing accurate enough models still remains a big challenge. In this contribution, we report the current developments in this field, discuss in silico modeling limitations, and review the successful application of this technique to different stages of the drug discovery process.

[1]  N. Cohen,et al.  Structure-based drug design and the discovery of aliskiren (Tekturna): perseverance and creativity to overcome a R&D pipeline challenge. , 2007, Chemical biology & drug design.

[2]  David C Fry,et al.  Protein-protein interactions as targets for small molecule drug discovery. , 2006, Biopolymers.

[3]  M. Mueckler,et al.  Transmembrane Segment 6 of the Glut1 Glucose Transporter Is an Outer Helix and Contains Amino Acid Side Chains Essential for Transport Activity* , 2008, Journal of Biological Chemistry.

[4]  V. Kairys,et al.  Using Protein Homology Models for Structure-Based Studies: Approaches to Model Refinement , 2006, TheScientificWorldJournal.

[5]  Alessandra Gianoncelli,et al.  Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screening. , 2008, Bioorganic & medicinal chemistry letters.

[6]  Jörg Rademann,et al.  Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking , 2008, Proceedings of the National Academy of Sciences.

[7]  Mihaly Mezei,et al.  Homology modeling and site-directed mutagenesis to identify selective inhibitors of endothelin-converting enzyme-2. , 2008, Journal of medicinal chemistry.

[8]  Rick Gussio,et al.  Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore. , 2006, Bioorganic & medicinal chemistry.

[9]  Thomas A. Halgren,et al.  Identifying and Characterizing Binding Sites and Assessing Druggability , 2009, J. Chem. Inf. Model..

[10]  S. Moro,et al.  Ligand-based homology modeling as attractive tool to inspect GPCR structural plasticity. , 2006, Current pharmaceutical design.

[11]  Krzysztof Palczewski,et al.  Non-commercial Research and Educational Use including without Limitation Use in Instruction at Your Institution, Sending It to Specific Colleagues That You Know, and Providing a Copy to Your Institution's Administrator. All Other Uses, Reproduction and Distribution, including without Limitation Comm , 2022 .

[12]  Bruno O Villoutreix,et al.  Proposed structural models of the prothrombinase (FXa–FVa) complex , 2006, Proteins.

[13]  J. Skolnick,et al.  How well is enzyme function conserved as a function of pairwise sequence identity? , 2003, Journal of molecular biology.

[14]  H Kubinyi.  HTS Technologies--IBC Informa Conference. , 2001, IDrugs : the investigational drugs journal.

[15]  A. Anderson.  The process of structure-based drug design. , 2003, Chemistry & biology.

[16]  J. Nosanchuk,et al.  Biological Function and Molecular Mapping of M Antigen in Yeast Phase of Histoplasma capsulatum , 2008, PloS one.

[17]  Claudio N. Cavasotto and Narender Singh.  Docking and High Throughput Docking: Successes and the Challenge of Protein Flexibility , 2008 .

[18]  Nir Ben-Tal,et al.  Model Structure of the Na+/H+ Exchanger 1 (NHE1) , 2007, Journal of Biological Chemistry.

[19]  Mohammed A Kashem,et al.  Discovery of potent and selective PKC-theta inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[20]  John O Trent,et al.  Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth , 2008, Molecular Cancer Therapeutics.

[21]  Matthieu Schapira,et al.  Structural genomics and drug discovery: all in the family. , 2008, Current opinion in chemical biology.

[22]  Hwangseo Park,et al.  Discovery of novel Cdc25 phosphatase inhibitors with micromolar activity based on the structure-based virtual screening. , 2008, Journal of medicinal chemistry.

[23]  Daniel Fischer,et al.  Servers for protein structure prediction. , 2006, Current opinion in structural biology.

[24]  Claudio N. Cavasotto,et al.  Scalaradial, a Dialdehyde‐Containing Marine Metabolite That Causes an Unexpected Noncovalent PLA2 Inactivation , 2007, Chembiochem : a European journal of chemical biology.

[25]  Ana M. Rojas,et al.  The Nod-Like Receptor (NLR) Family: A Tale of Similarities and Differences , 2008, PloS one.

[26]  Hermann Schindelin,et al.  Structural and Mechanistic Insights into Lunatic Fringe from a Kinetic Analysis of Enzyme Mutants* , 2009, Journal of Biological Chemistry.

[27]  Jacquelyn S Fetrow,et al.  Structure-based active site profiles for genome analysis and functional family subclassification. , 2003, Journal of molecular biology.

[28]  Marc A. Martí-Renom,et al.  MODBASE: a database of annotated comparative protein structure models and associated resources , 2005, Nucleic Acids Res..

[29]  Konrad Büssow,et al.  Automated technologies and novel techniques to accelerate protein crystallography for structural genomics , 2008, Proteomics.

[30]  Claudio N. Cavasotto,et al.  Conformational Sampling of Protein Flexibility in Generalized Coordinates: Application to Ligand Docking , 2005 .

[31]  C. Cavasotto,et al.  The binding mode of petrosaspongiolide M to the human group IIA phospholipase A(2): exploring the role of covalent and noncovalent interactions in the inhibition process. , 2009, Chemistry.

[32]  Steven M. Muskal,et al.  Interrogating the Druggable Genome with Structural Informatics , 2007 .

[33]  K. Lundstrom,et al.  Structural genomics and drug discovery , 2007, Journal of cellular and molecular medicine.

[34]  Hiroki Shirai,et al.  Identification of the Druggable Concavity in Homology Models Using the PLB Index , 2007, J. Chem. Inf. Model..

[35]  Emil Alexov,et al.  Predicting 3D structures of transient protein-protein complexes by homology. , 2006, Biochimica et biophysica acta.

[36]  A. Sali,et al.  Comparative protein structure modeling of genes and genomes. , 2000, Annual review of biophysics and biomolecular structure.

[37]  M. Jacobson,et al.  Virtual screening against highly charged active sites: identifying substrates of alpha-beta barrel enzymes. , 2005, Biochemistry.

[38]  Michael Levitt,et al.  Growth of novel protein structural data , 2007, Proceedings of the National Academy of Sciences.

[39]  Lupei Du,et al.  Computational studies of the binding site of α1A-adrenoceptor antagonists , 2008, Journal of molecular modeling.

[40]  Emil Alexov,et al.  omology-based modeling of 3 D structures of protein – protein complexes using lignments of modified sequence profiles etras , 2008 .

[41]  Tom L. Blundell,et al.  Keynote review: Structural biology and drug discovery , 2005 .

[42]  E. Hazai,et al.  Homology modeling of breast cancer resistance protein (ABCG2). , 2008, Journal of structural biology.

[43]  Udo Höweler,et al.  Simulations of a G protein‐coupled receptor homology model predict dynamic features and a ligand binding site , 2008, FEBS letters.

[44]  P. Fernandes,et al.  Technological advances in high-throughput screening. , 1998, Current opinion in chemical biology.

[45]  Richard M. Jackson,et al.  An evaluation of automated homology modelling methods at low target-template sequence similarity , 2007, Bioinform..

[46]  R. Hilgenfeld,et al.  Utility of homology models in the drug discovery process , 2004, Drug Discovery Today.

[47]  Dora M Schnur.  Recent trends in library design: 'rational design' revisited. , 2008, Current opinion in drug discovery & development.

[48]  Catherine L. Worth,et al.  Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery , 2006, Philosophical Transactions of the Royal Society B: Biological Sciences.

[49]  Claudio N. Cavasotto,et al.  Ligand docking and structure-based virtual screening in drug discovery. , 2007, Current topics in medicinal chemistry.

[50]  Claudio N. Cavasotto,et al.  Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. , 2008, Journal of medicinal chemistry.

[51]  Hugo O Villar,et al.  Using NMR for ligand discovery and optimization. , 2004, Current opinion in chemical biology.

[52]  Sebastian Radestock,et al.  Homology Model-Based Virtual Screening for GPCR Ligands Using Docking and Target-Biased Scoring , 2008, J. Chem. Inf. Model..

[53]  Hwangseo Park,et al.  Discovery of novel alpha-glucosidase inhibitors based on the virtual screening with the homology-modeled protein structure. , 2008, Bioorganic & medicinal chemistry.

[54]  Stefano Costanzi,et al.  On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. , 2008, Journal of medicinal chemistry.

[55]  K. Ginalski.  Comparative modeling for protein structure prediction. , 2006, Current opinion in structural biology.

[56]  Mario G. Cardozo,et al.  Discovery of potent and selective PKC-θ inhibitors , 2007 .

[57]  G. Montelione,et al.  Contributions to the NIH-NIGMS Protein Structure Initiative from the PSI Production Centers. , 2008, Structure.

[58]  Marcel L Verdonk,et al.  Automated Protein–Ligand Crystallography for Structure‐Based Drug Design , 2006, ChemMedChem.

[59]  Ning Ren,et al.  Molecular modeling aided design of nicotinic acid receptor GPR109A agonists. , 2008, Bioorganic & medicinal chemistry letters.

[60]  David P. Westfall.  Adrenoceptor Antagonists , 2003 .

[61]  Claudio N. Cavasotto,et al.  Protein flexibility in ligand docking and virtual screening to protein kinases. , 2004, Journal of molecular biology.

[62]  T. Blundell,et al.  Structural biology and drug discovery. , 2005, Drug discovery today.

[63]  Jianlin Cheng.  A multi-template combination algorithm for protein comparative modeling , 2008, BMC Structural Biology.

[64]  Hong Zhu,et al.  Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays. , 2007, Bioorganic & medicinal chemistry letters.

[65]  Stefano Moro,et al.  Linear and Nonlinear 3D-QSAR Approaches in Tandem with Ligand-Based Homology Modeling as a Computational Strategy To Depict the Pyrazolo-Triazolo-Pyrimidine Antagonists Binding Site of the Human Adenosine A2A Receptor , 2008, J. Chem. Inf. Model..

[66]  John D. Westbrook,et al.  The Protein Model Portal , 2008, Journal of Structural and Functional Genomics.

[67]  Gerhard Klebe,et al.  Development of Benzophenone‐Based Farnesyltransferase Inhibitors as Novel Antimalarials , 2008, ChemMedChem.

[68]  Ashish V. Tendulkar,et al.  Functional sites in protein families uncovered via an objective and automated graph theoretic approach. , 2003, Journal of molecular biology.

[69]  Claudio N. Cavasotto,et al.  2,3‐Dihydro‐1‐Benzofuran Derivatives as a Series of Potent Selective Cannabinoid Receptor 2 Agonists: Design, Synthesis, and Binding Mode Prediction through Ligand‐Steered Modeling , 2009, ChemMedChem.

[70]  Arne Elofsson,et al.  Using multiple templates to improve quality of homology models in automated homology modeling , 2008, Protein science : a publication of the Protein Society.

[71]  Robert C. Edgar,et al.  Multiple sequence alignment. , 2006, Current opinion in structural biology.

[72]  Francesco Musiani,et al.  A model‐based proposal for the role of UreF as a GTPase‐activating protein in the urease active site biosynthesis , 2007, Proteins.

[73]  Heidi J. Imker,et al.  Prediction and assignment of function for a divergent N-succinyl amino acid racemase. , 2007, Nature chemical biology.

[74]  Ram Samudrala,et al.  Improving the accuracy of template-based predictions by mixing and matching between initial models , 2008, BMC Structural Biology.

[75]  Sharangdhar S. Phatak,et al.  6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction. , 2009, Journal of medicinal chemistry.

[76]  Claudio N. Cavasotto,et al.  Structure-based development of target-specific compound libraries. , 2006, Drug discovery today.

[77]  D. Langley,et al.  Expanding GPCR homology model binding sites via a balloon potential: A molecular dynamics refinement approach , 2008, Proteins.